Testosterone Nasal Gel: How Natesto Works For Low T

Testosterone nasal gel is an FDA-approved formulation that delivers testosterone directly through the nasal mucosa to treat diagnosed hypogonadism in adult men. Sold under the brand name Natesto, it's the only nasal testosterone product currently approved in the United States (FDA, 2025). Unlike transdermal gels and injections, Natesto requires three daily applications but may reduce the risk of unintentional testosterone transfer compared to topical gels. Marek Health offers testosterone replacement through telehealth, and nasal gel is one of several delivery methods a provider may consider after reviewing lab work and clinical history.

This article won't cover compounded nasal testosterone formulations, which aren't FDA-approved and carry different regulatory and quality considerations.

What Is Testosterone Nasal Gel?

Natesto is a prescription androgen hormone classified as a Schedule III controlled substance (FDA, 2025). It's indicated for replacement therapy in adult men with diagnosed hypogonadism caused by primary testicular failure or hypogonadotropic (pituitary/hypothalamic) dysfunction.

The FDA has not approved Natesto for age-related testosterone decline. That limitation remains in the current label.

Each pump actuation delivers 5.5 mg of testosterone. The standard dose is 11 mg per application (one actuation per nostril), three times daily, for a total of 33 mg per day. In the Phase 3 registration trial, approximately 90% of participants in the fixed-dose arm achieved testosterone levels within the study-defined reference range by Day 90 (FDA, 2025).

How Is Natesto Applied?

Before each dose, patients blow their nose gently. They then depress the pump once into each nostril, tilting the actuator so the gel contacts the lateral nasal wall. After application, patients press the nostrils just below the bridge and lightly massage. No blowing the nose or sniffing for one hour afterward (FDA, 2025).

The FDA prescribing information recommends spacing the three daily doses approximately 6 to 8 hours apart.

If a dose is missed, patients should take it as soon as possible unless the next dose is near. Double doses aren't recommended. Patients experiencing severe rhinitis should temporarily stop Natesto until symptoms resolve. If nasal symptoms persist, a provider may recommend an alternative formulation.

Who Should Avoid Testosterone Nasal Gel?

Natesto is contraindicated in men with breast cancer or known or suspected prostate cancer. It's also contraindicated for women who are pregnant or breastfeeding because of virilization risk (FDA, 2025).

Men with existing nasal conditions aren't recommended candidates. That includes a history of sinus surgery, nasal fracture within the prior six months, or mucosal inflammatory disorders such as Sjogren's syndrome. Providers should also know about any history of sleep apnea, diabetes, heart disease, or kidney or liver disease before prescribing. A full picture of a patient's health starts with lab testing and a clinical evaluation.

What Are the Side Effects of Nasal Testosterone?

The most common adverse reactions (3% or more in clinical trials) include increased PSA, headache, rhinorrhea, epistaxis, nasal discomfort, nasopharyngitis, bronchitis, upper respiratory infection, sinusitis, and nasal scabbing (FDA, 2025).

Serious risks include venous thromboembolism (deep vein thrombosis, pulmonary embolism), blood pressure increases, polycythemia (elevated hematocrit), worsening of benign prostatic hyperplasia, mood changes, and sleep apnea.

The FDA's 2025 class-wide labeling update added blood pressure warnings based on TRAVERSE trial data while removing the prior cardiovascular boxed warning (FDA, 2025; Lincoff et al., 2023). That trial studied 5,246 men with hypogonadism and cardiovascular risk factors. The primary MACE endpoint met noninferiority criteria (7.0% vs. 7.3%), though the testosterone group showed higher incidence of atrial fibrillation, acute kidney injury, and pulmonary embolism (Lincoff et al., 2023).

Does Nasal Testosterone Affect Fertility?

All exogenous testosterone, including Natesto, may suppress spermatogenesis through feedback inhibition of pituitary FSH (FDA, 2025). This is a class-wide concern, not specific to one formulation.

Natesto's short-acting pharmacokinetic profile has drawn clinical interest. Because it doesn't maintain elevated serum testosterone around the clock, researchers at the University of Miami Miller School of Medicine have conducted a Phase IV clinical trial studying whether it may partially preserve pituitary signaling to the testes (University of Miami, 2019). Whether Natesto's short-acting profile affects spermatogenesis differently from other formulations remains under investigation, and no completed peer-reviewed trial has confirmed fertility preservation with any testosterone product. Individual results are unpredictable, and suppression can still occur.

Men who may want to preserve fertility should discuss fertility and TRT with a provider before and during treatment, as effects on spermatogenesis may change over time. Understanding testosterone changes by age can also help frame the decision.

How Does Natesto Compare to Injections and Topical Gels?

The trade-off with Natesto is dosing burden. Three daily applications demand more consistency than a weekly injection. The advantages include a shorter-acting daily testosterone profile that may result in less pronounced hormonal fluctuation, and a lower risk of transferring testosterone to household contacts compared to topical gels. Men exploring symptoms of low testosterone with their provider can weigh these factors against their daily routine and lifestyle.

What Should Patients Monitor During Treatment?

Serum total testosterone should be checked starting one month after beginning Natesto. The FDA prescribing information outlines specific monitoring thresholds that guide providers in determining whether to continue, adjust, or discontinue therapy (FDA, 2025).

Clinical guidelines, including those from the Endocrine Society, outline recommended monitoring intervals for hematocrit and other markers, which providers adjust based on the individual patient's risk profile (Bhasin et al., 2018). The prescribing provider determines which biomarkers to monitor and how often, based on the patient's clinical profile and current guideline recommendations (Mulhall et al., 2018). Men already managing reference range questions should discuss how Natesto fits their existing monitoring plan.

Drug interactions include diabetes medications (testosterone may lower blood glucose), anticoagulants like warfarin, corticosteroids (which may increase fluid retention), and other nasal medications. Patients should inform their provider about all current medications, including over-the-counter and nasal products, before starting Natesto. The medication should be stored at room temperature (68-77 degrees Fahrenheit). Replace the dispenser when the piston reaches the indicator arrow.

A hormone blood test before and during treatment gives the clearest picture of how the body responds. Men who aren't sure whether their symptoms point to low testosterone should start with a clinical evaluation. All prescribing decisions should be made collaboratively between the patient and provider, based on lab results, symptoms, and individual health goals.

Disclaimer: This blog post is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making changes to your health routine.

FAQs

How does testosterone nasal gel differ from injectable TRT?

Natesto is applied three times daily through the nose, while injections (testosterone cypionate or enanthate) are typically administered weekly or biweekly. Nasal gel produces a more steady daily hormone profile with less pronounced peaks and troughs. It also carries a lower risk of transferring testosterone to others compared to transdermal gels, which require skin application.

Does Natesto require a prescription?

Yes. Testosterone is a Schedule III controlled substance. Prescribing requires a confirmed diagnosis of hypogonadism based on two morning blood draws showing total testosterone consistently below 300 ng/dL, plus clinical symptoms. The diagnosis and prescription must come from a licensed provider.

Can testosterone nasal gel affect sperm production?

All exogenous testosterone may suppress spermatogenesis. Whether Natesto's short-acting profile affects spermatogenesis differently from other formulations remains under investigation, and no completed peer-reviewed trial has confirmed fertility preservation with any testosterone product. Suppression can still occur, and individual outcomes are unpredictable. Men who may want to preserve fertility should discuss this with a provider before and during treatment.

What nasal side effects does Natesto cause?

The most commonly reported nasal side effects include rhinorrhea (runny nose), epistaxis (nosebleeds), nasal discomfort, nasopharyngitis, and nasal scabbing. Most were mild or moderate in clinical trials. Severe rhinitis may require temporarily stopping the medication.

Is testosterone nasal gel FDA-approved?

Yes. Natesto is FDA-approved for testosterone replacement in adult men with diagnosed primary hypogonadism or hypogonadotropic hypogonadism. It is not approved for age-related testosterone decline.

How long does it take for Natesto to reach therapeutic levels?

Serum testosterone should be checked starting one month after beginning treatment. In the Phase 3 trial, approximately 90% of men in the fixed-dose arm achieved levels within the study-defined reference range by Day 90, according to the FDA prescribing information.

What lab monitoring is needed while on Natesto?

Providers determine which biomarkers to monitor and how often, guided by clinical guidelines from the Endocrine Society and AUA, and adjusted to the individual patient's risk profile. If testosterone levels or hematocrit fall outside guideline-recommended ranges, treatment adjustments are needed.

References

• N Engl J Med. 2023;389:107-117

• J Clin Endocrinol Metab. 2018;103(5):1715-1744

• J Urol. 2018;200:423-432

• FDA. Natesto Prescribing Information (revised 07/2025)

• FDA. Class-Wide Labeling Changes for Testosterone Products (02/2025)

• University of Miami Miller School of Medicine. Nasal Gel Treats Low Testosterone Without Harming Sperm Production (2019)